Fish Vaccines

Adams, Alexandra; Subasinghe, R. P.

doi:10.1002/9781119506287.ch9

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immersion vaccination has several advantages over injection and oral administration, such as cost-effectiveness, low-stress induction, low labor costs, suitability for small fish, and the ability to vaccinate numerous simultaneously [ 17 , 43 , 44 ]. However, some crucial disadvantages remain, especially the need for high amounts of vaccines, weak immune responses, and low protection in small fish [ 45 , 46 ]. Additionally, the greatest limitation of this strategy is that the most effective age and size of fish for immersion vaccination are unclear in many fish species, including Nile tilapia.…”

Section: Discussionmentioning

confidence: 99%

First Investigation of the Optimal Timing of Vaccination of Nile Tilapia (Oreochromis niloticus) Larvae against Streptococcus agalactiae

Kumwan,

Bunnoy,

Chatchaiphan

et al. 2023

Vaccines

View full text Add to dashboard Cite

To investigate early immune responses and explore the optimal vaccination periods, Nile tilapia at 1, 7, 14, 21, 28, 35, and 42 days after yolk sac collapse (DAYC) were immersed in formalin-killed Streptococcus agalactiae vaccine (FKV-SA). A specific IgM was first detected via ELISA in the 21 DAYC larvae (0.108 g) at 336 h after vaccination (hav), whereas in the 28–42 DAYC larvae (0.330–0.580 g), the specific IgM could be initially detected at 24 hav. qRT–PCR analysis of the TCRβ, CD4, MHCIIα, IgHM, IgHT, and IgHD genes in 21–42 DAYC larvae immunized with the FKV-SA immersion route for 24, 168, and 336 hav revealed that the levels of most immune-related genes were significantly higher in the vaccinated larvae at all DAYCs than in the control larvae (p < 0.05) at 336 hav. Immunohistochemistry demonstrated stronger IgM signals in the gills, head kidney, and intestine tissues at 21, 28, and 35 DAYC in all vaccinated larvae compared with the control. Interestingly, at all DAYCs, FKV-SA larvae exhibited significantly higher survival rates and an increased relative percent survival (RPS) than the control after challenge with viable S. agalactiae, particularly in larvae that were immunized with FKV-SA at 168 and 336 hav (p < 0.05).

show abstract

Section: Discussionmentioning

confidence: 99%

First Investigation of the Optimal Timing of Vaccination of Nile Tilapia (Oreochromis niloticus) Larvae against Streptococcus agalactiae

Kumwan,

Bunnoy,

Chatchaiphan

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

“…Effectively, the challenge in the use of the live attenuated vaccine is to guarantee fish protection and impossibility of the reversion of the bacterial to pathogen. Some important considerations that should be taken into account include: fish species to be vaccinated, status of the immune system of the fish, production cycle and life history of the aquaculture system, which diseases need to control in aquaculture, when do these diseases occur (seasonal distribution of diseases in the aquarium), farming technology (handling and mechanization), environment (temperature and salinity), stress factors and nutrition (Adams, 2016; Assefa & Abunna, 2018).…”

Section: Fish Vaccinationmentioning

confidence: 99%

Advances in vaccines developed for bacterial fish diseases, performance and limits

Hamed¹,

Tapia‐Paniagua

Moriñigo

et al. 2021

Aquaculture Research

View full text Add to dashboard Cite

In aquaculture, resolving disease problems with antibiotic‐medicated food is a general practice but has led to antibiotic resistance of several pathogens, resulting in a higher dose requirement for effective control; this matter is increasing public concern. Scientists are focusing more to support prophylactic strategy in aquaculture that uses vaccines as a preventive measure. Beneficing of the new technology emerging, three principal forms of vaccines are in advance: inactivated form, live attenuated form and DNA‐based vaccine form. Regarding some diseases, fish vaccination was employed successfully to protect the farmed fish from the common pathogens. Some vaccines are licensed and commercially available overall the world, others still in experimental phases. Autogenous vaccines are specifically developed and their uses are restricted to defined sites. The administration routes, the ambient conditions, the heterogeneity of biochemical and serological characteristics of pathogens remain the biggest obstacle in developing an effective commercial vaccine. In this review, we intend to update the advances acquired in the fish vaccine and we discuss the advantages, the limitations, and the challenges encountered in this promising preventive approach in aquaculture.

show abstract

“…At present many small companies and 19 large companies make fish vaccines worldwide (Brudeseth et al 2013). There are currently 24 commercially available vaccinations, up from two in the 1980s, when they were first utilized in fisheries and aquaculture (Adams & Subasinghe 2019;Shefat 2018). Vaccines are used for a large number of fish species: Tilapia, sea bream, yellow tail, rainbow trout and Atlantic salmon (Assefa & Abunna 2018).…”

mentioning

confidence: 99%

“…To use commercial vaccines there should be knowledge of nutrition, stress factors, life cycle, and immune system status. Most vaccines produced at commercial level have adjuvants and are injected intraperitoneally (Adams & Subasinghe 2019).…”

mentioning

confidence: 99%

Untitled

2023

JSM

View full text Add to dashboard Cite

The development and growth of the fisheries and aquaculture industries are significantly hampered by illnesses. It is critical to combat pathogenic illnesses, especially bacterial ones. Furunculosis in salmon is mostly brought on by Aeromonas salmonicida in rainbow and brown trout. To control this pathogen, vaccines have been identified as a significant tool. In the present study, we have formulated an inactivated vaccine with oil as an adjuvant and estimated its efficacy. The lethal dose of ArS-Pak-19, was calculated and injected intraperitoneally to the fishes. To analyze the infection, samples of kidney, liver, spleen, and blood were collected at specific times. To estimate the immunogenicity of the vaccine, an experiment was designed. One hundred sixty fishes were distributed into 8 tanks including, six experimental groups and two control groups with its replicates, vaccines injected intraperitoneally 1.6 × 10 7 , 1.6 × 10 8 , and 1.6 × 10 9 and blood samples were taken fortnightly for 56 days to calculate the antibodies titers. After immunization these groups were challenged with Aeromonas salmonicida (ArS-Pak-19) intraperitoneally. At 7 th day of post infection, it appeared in the liver, spleen, and kidney. The relative percentage of survival was estimated with control groups at 30 days after challenge. The relative percentage of survival was 80%. The IgM titers were higher at 24 days of post immunization. We also analyzed that antibodies non-specifically bound with the A-layer of Aeromonas salmonicida. The findings of this study offer evidence that vaccinations boost fishes immunity and serve as a roadmap to further vaccination initiatives.

show abstract

Fish Vaccines

Cited by 6 publications

References 15 publications

First Investigation of the Optimal Timing of Vaccination of Nile Tilapia (Oreochromis niloticus) Larvae against Streptococcus agalactiae

First Investigation of the Optimal Timing of Vaccination of Nile Tilapia (Oreochromis niloticus) Larvae against Streptococcus agalactiae

Advances in vaccines developed for bacterial fish diseases, performance and limits

Untitled

Contact Info

Product

Resources

About